Table 5.

Early outcome of patients with LFLG AS treated with TAVR or SAVR.

Outcomes	SAVR, n = 401		TAVR, n = 389		p-value
	Missing		Missing
30-Day death	0	18 (4.5)	0	13 (3.3)	0.407
Valve migration	0	0 (0.0)	2	7 (1.8)	0.007
Myocardial infarction	3	7 (1.8)	0	1 (0.3)	0.036
Major vascular complications	25	1 (0.3)	0	8 (2.1)	0.022
Permanent pacemaker	4	18 (4.5)	0	44 (11.3)	<0.001
Stroke	5	5 (1.3)	0	7 (1.8)	0.540
Cardiogenic shock	5	35 (8.8)	2	8 (2.1)	<0.001
Blood transfusion	25	210 (55.9)	2	41 (10.6)	<0.001
Transfused RBC units	0	2.0 ± 3.1	0	0.2 ± 0.8	<0.001
AKI	11	38 (9.7)	1	11 (2.8)	<0.001
PCI	3	1 (0.3)	0	0 (0.0)	0.323
Tamponade	4		0		0.319
Requiring surgery		6 (1.5)		2 (0.5)
Requiring percutaneous treatment		1 (0.3)		2 (0.5)
Infectious complications	11	24 (6.2)	0	15 (3.9)	0.148
PVL	37		0		<0.001
No/trivial		326 (89.6)		217 (55.8)
Mild		32 (8.8)		144 (37.0)
Moderate		4 (1.1)		25 (6.4)
Severe		2 (0.6)		3 (0.8)
AV pick gradient, mmHg	91	23.1 ± 10.3	22	14.6 ± 8.6	<0.001
AV mean gradient, mmHg	95	12.7 ± 6.8	7	7.8 ± 5.0	<0.001
Intensive care unit stay, days	7	4.0 ± 6.7	7	1.4 ± 2.3	<0.001

Continuous variables are reported as mean and standard deviation. Categorical variables are reported as counts and percentages (in parentheses).

AKI, acute kidney injury; AV, aortic valve; PCI, percutaneous coronary intervention; PVL, paravalvular leak; RBC, red blood cells; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement.